



#11
10/27/01

TECH CENTER 1600/2900

OCT 23 2001

RECEIVED

In re PATENT APPLICATION OF

BOX SEQUENCE

Darrell R. Anderson et al.

Group Art Unit: 1644

Application No. 09/576,424

Filed: May 22, 2000

Title: Identification of Unique Binding Interactions Between Certain Antibodies and the Human B7.1 and B7.2 Stimulatory Antigens

* * * * *

RESPONSE WITH SEQUENCE LISTING

Hon. Commissioner of Patents
Washington, D.C. 20231


Sir:

In response to the Examiner's Official Communication's dated September 20, 2001, attached please find a copy of the "Sequence Listing" in computer readable format along with a Statement to Support Filing and Submission in Accordance with 37 C.F.R. §1.821-1.825.

Applicant respectfully submits that the content of the sequence listing information recorded in computer readable form is identical to the written sequence listing and includes no new matter.

Respectfully submitted,

Pillsbury Winthrop LLP

By: 

Bonnie D. Weiss

Registration No. 43,255

1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2000
(703) 905-2500 Facsimile

Date: October 19, 2001

Enclosure: Statement to Support Filing
Sequence Listing (including electronic copy)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Darrell R. Anderson et al.

Appl. No.: 09 576,424

Series Code ↑ Serial No. ↑

Filed: May 22, 2000

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

Group Art Unit 1644

Examiner: Phillip Gambel

Atty. Dkt. P 0275681 1995-30-0235CP2

M# Client Ref

Appl. Title: Identification of Unique Binding
Interactions Between Certain Antibodies
and the Human B7.1 and B7.2
Stimulatory Antigens

Date: October 19, 2001

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated herein by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☒ NOT made
B. ☐ Withdrawn
C. ☐ made herewith
D. ☐ made previously

For B & C
See **Required**
Separate Paper
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	**minus 20	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus 3	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)			add	+ \$280/\$140 =	+ \$0 104/204
5. Original due Date: October 20, 2001		<input type="checkbox"/> NONE			
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) \$110/\$55 = (2 mos) \$400/\$200 = (3 mos) \$920/\$460 = (Usable only for ≤ 2mo.OA --- 4 mos) \$1,440/\$720= (Usable only for 30 day/1mo.OA --- 5 mos) \$1,960/\$980=	+ \$0		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8. Extension Fee Attached			+ \$0		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee			+ \$110/\$55 + \$0 148/248		
10. If IDS attached requires Official Fee under Rule 97 (c), add			+ \$130 + \$0 126		
or if Rule 97(d) Request add			+ \$180 + \$0 126		
11. After-Final Request Fee per rules 129(a) and 17(r)			+ \$740/370 + \$0 146/246		
12. No. of additional inventions for examination per Rule 129(b).....			x \$740/370 ea + \$0 149/249		
13. Request for Continued Examination (RCE)			+ \$740/370 + \$0 1179/1279		
14. Petition fee for			+ \$0		
15. TOTAL FEE ENCLOSED =			\$0		

15.

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 0275681

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT **does not authorize** charge of the **issue fee** until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Bonnie D. Weiss

Sig:

Reg. No. 43,255

Fax:

Tel:

(703) 905-2500

(703) 905-2219

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Atty/Sec: BDW/ngm

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

RECEIPT FROM PTO FOR INDICATED ITEMS

#27

(Do NOT Use for New or Continuing Applications of Any Kind)
 Use 2 postcards for all New Applns. (cont/Div/CIP, too)
Use this sheet when filing CPA

Appln. No: 09/576,424	Atty: Robin L. Teskin
First Inventor: ANDERSON et al	Date: October 19, 2001
	Matter No: 0275681
	Client No: 037003

ENCLOSED:

☒ Response/Amendment ☐ Appendix ☐ Cover Sheet ☐ Cited/Listed Documents

☐ Completion Request for R 53(f)/PCT Nat.

No. of Pages Abstract

No. of Pages Spec and Claims

No. of Numbered Claims Only

No. of Sheets of Drawings (Figs



☐ 1 Set Formal ☐ 1 Set Informal ☐ Cover Letter

☐ Declaration ☐ # of pages

☐ Assignment ☐ Cover Sheet

☐ Small Entity Declaration

☐ Extension Petition (PAT-111)

☐ No. of Priority Documents

☐ IDS Letter ☐ Cited Appln(s) ☐ Foreign Sch Rep/OA

☐ PTO-1449 ☐ Cited Documents

☐ Issue Fee Transmittal Form PTOL-85(b) + (c)

\$ 0.00 Fee (Check)

OTHER: Sequence Listing, Diskette, Statement in Support

Current DUE DATE: 10/20/01

(Submit Single Copy Only)

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7.

Other: _____

Applicant must provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.